Analysis of patient cost for recombinant human platelet-derived growth factor therapy as the first-line treatment of the insured patient with a diabetic foot ulcer.

Advances in skin & wound care

Volumn 22, Issue 4, 2009, Pages 167-171

  Lantis 2nd , John C ^a   Boone, Deva ^b   Gendics, Cindy ^b   Todd, George ^b  

^a ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENIC FACTOR; PLATELET DERIVED GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR BB; PLATELET-DERIVED GROWTH FACTOR BB;

ALGORITHM; ARTICLE; CLASSIFICATION; DEBRIDEMENT; DIABETIC FOOT; DRUG EFFECT; ECONOMICS; HEALTH CARE COST; HEALTH INSURANCE; HUMAN; RETROSPECTIVE STUDY; STATISTICAL MODEL; UNITED STATES; WOUND HEALING;

ALGORITHMS; ANGIOGENESIS INDUCING AGENTS; DEBRIDEMENT; DIABETIC FOOT; HEALTH CARE COSTS; HUMANS; INSURANCE, HEALTH; MODELS, ECONOMIC; PLATELET-DERIVED GROWTH FACTOR; RETROSPECTIVE STUDIES; UNITED STATES; WOUND HEALING;

MLCS; MLOWN;

EID: 77952793213     PISSN: None     EISSN: 15388654     Source Type: Journal    
DOI: 10.1097/01.asw.0000305466.25177.a8     Document Type: Article

References (0)